Company intelligence / Profile preview
60 Degrees Pharmaceuticals
Washington, District of Columbia, United States60degreespharma.com ↗
- Ownership
- Public · SXTP
- Development stage
- Commercial
01
Overview
Successfully achieved FDA approval for ARAKODA® (tafenoquine) for malaria prevention in 2018, which has been on the market since late 2019. Reported 140% revenue growth in 2024, driven by Arakoda® sales. Currently conducting clinical trials and market expansion.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
U.S. Armyresearch organizations in the U.S., Australia, and Singapore
04
Financials
- Market cap
- $3.2M
- Total revenue
- $1M
- Enterprise value
- $2.4M
Beyond the preview
Go deeper on 60 Degrees Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 60 Degrees Pharmaceuticals.